Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929031 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 562
- Enrollment target
NCT01929031 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 562 participants.
The verdict
NCT01929031, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 562 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy of a combination product containing ibuprofen 400 mg and caffeine 100 mg versus either ingredient alone as well as placebo for the treatment of post-surgical dental pain over an eight-hour period followed by a single dose of study medication (study stage 1). A secondary objective is to evaluate efficacy of multiple doses of the combination in comparison to ibuprofen alone over a 5-day post-surgical period (study stage 2).
Interventions
- DRUG ibuprofen
- DRUG ibuprofen + caffeine
- DRUG caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01929031
The ClinicalTrials.gov registry entry for NCT01929031 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ibuprofen is the first listed.
NCT01929031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01929031 about?
NCT01929031 is a clinical study titled "Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain". The primary objective of this study is to compare the efficacy of a combination product containing ibuprofen 400 mg and caffeine 100 mg versus either ingredient alone as well as placebo for the treatment of post-surgical dental pain over an eight-hour period followed by a single dose of study medica...
What is the current status of trial NCT01929031?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 562 participants. The study started on 2013-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01929031?
The interventions under investigation include: ibuprofen (DRUG), ibuprofen + caffeine (DRUG), caffeine (DRUG).
Who is sponsoring clinical trial NCT01929031?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.